HDFC Life Insurance Company Ltd

Meeting Details

• Date: October 15, 2026
• Type: earnings call; audio recording posted on company website
• Organiser: HDFC Life Insurance Company Limited
• Key participant: Executive Director & CFO
• Purpose: discuss results for quarter and half-year ended September 30, 2026
• Recording: audio recording available on company website

Overview

• Board approved standalone and consolidated H1 FY27 results for half-year ended 30 September 2026.
• VNB grew 12%; VNB margin 24.7%; PAT ₹1,119 crore.
• AUM including subsidiary reached ₹5.9 lakh crore; standalone AUM ₹4.1 trillion.
• Solvency ratio healthy at 180%; 13M/61M persistency 83%/66%.
• Total Premium ₹39,569 crore; New Business Premium ₹19,126 crore; Renewal Premium ₹20,443 crore.
• Total expenses to total premium 22.3%; ROE 12.3%.
• IRDAI consulting papers on insurance distribution highlighted in regulatory context.

Financial results

• Unaudited standalone and consolidated results for quarter and half-year ended 30 Sep 2026 approved; limited review reports enclosed.
• Review conducted under SEBI LODR and IRDAI requirements; audit opinion not provided.

Fundraising / capital actions

• In-principle approval for raising funds via NCDs up to ₹500 crore in one or more tranches.
• NCDs to be offered on private placement basis; subject to applicable regulations.

IFSC office

• Establishment of IFSC Insurance Office at GIFT IFSC to leverage IFSC ecosystem.
• Subject to IRDAI, IFSC Authority, and shareholder approvals via postal ballot.

Shareholder approvals

• Postal ballot to seek shareholder approval for IIO establishment; notice to be issued.

Regulatory / compliance

• IRDAI Ind AS adoption deferred; forbearance granted until 1 April 2027.
• IRDAI circulars and SEBI LODR compliance; results to be published by Oct 30, 2026.
• GST ITC tax demand disclosed as contingent liability; appeals filed.

Other disclosures

• Employee stock options: 114,000 equity shares allotted in Q2 FY27.
• Subsidiaries' interim results not reviewed; not material to the group.

Meeting Details

• Date: October 15, 2026; time and venue not disclosed.

Key Agenda Items

• Unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026.
• Raising funds via private placement of subordinated Non-Convertible Debentures.

Other Notes

• Trading window closed October 1–17, 2026 for promoters, designated persons and relatives.

Grant of ESOP and PRSU

• N&C Committee approved grant of 23,85,355 equity stock options under ESOP 2025.
• Grant price fixed at Rs 531.60 per option; vesting over three years.
• Vesting schedule: 30% after 1 year, 30% after 2 years, 40% after 3 years.
• Exercisable within four years from each vesting date; lapse if not exercised.
• Grant of 11,05,140 PRSUs under Performance RSU Scheme 2025.
• Vesting 30%/30%/40% over years 1–3; 4-year exercise window.

GST Appeal Update

• Appeal order dated September 10, 2026 confirms total tax demand Rs 3,365.15 crore.
• Tax demand includes interest and penalty; company will appeal to GST Appellate Tribunal.
• No adverse material impact on financial operations.
• Period involved remains July 1, 2017 to March 31, 2022.

Meeting Details

• Sep 11, 2026 — UBS India Summit 2026, Mumbai; senior management to interact with investors.
• Sep 18, 2026 — Jefferies 5th India Forum, Gurgaon; group meeting.
• Sep 22, 2026 — JP Morgan India Conference, Mumbai; meeting type not specified.

Participants

• Key participants: senior management from HDFC Life.

Purpose

• Purpose: investor interaction as part of investor conferences.

Additional Notes

• Investor presentation already hosted on the company website.

ESOS Allotment

• On August 26, 2026, the Stakeholders' Relationship Committee allotted 1,14,000 equity shares under ESOS to eligible option holders.
• Post allotment, paid-up capital stands at ₹21,72,58,89,810 across 2,17,25,88,981 shares of ₹10.

Approval details

• IRDAI approved 5-year re-appointments of two executive directors.
• Vibha Padalkar to continue as MD & CEO for 5 years from Sep 12, 2026.
• Niraj Shah to continue as ED & CFO for 5 years from Apr 26, 2026.
• AGM on 16 July 2026 approved the proposals with requisite majority.
• DINs: Padalkar 01682810; Shah 09516010.

Regulatory confirmation

• IRDAI communication dated 19 Aug 2026 confirms approval.

Meeting Details

• Aug 14, 2026: EmkayConfluence 2026 investor meet; place not disclosed.
• Aug 19, 2026: Motilal Oswal 22nd Annual Global Investor Conference 2026; group meeting in Mumbai.
• Aug 28, 2026: Morgan Stanley: India Financials Investors Group Trip; place not disclosed.

Participants

• Senior management to participate in investor meetings.

Purpose

• Purpose: investor interaction and discussion of financial results.

Additional Notes

• Investor presentation already hosted on the company website.